波士顿科学Boston Scientific Corporation (BSX) 2011年年度报告「NYSE」.pdf

1、2011 ANNUAL REPORTInnovation.Its at the core of everything we do.2 Letter to Our Employees and Stockholders Improving Lives6 Jenny is running today,but not to the emergency room,thanks to a groundbreaking new treatment delivered by the Alair Bronchial Thermoplasty System.8 Evelyn appreciates freedom

2、 from anticoagulant drugs now that she has the WATCHMAN Left Atrial Appendage Closure Device.1 10 Bachok credits the ENERGEN Implantable Cardioverter Defibrillator(ICD)with saving him from sudden cardiac arrest.12 Sanjibs energy has returned and he is enjoying his life after receiving a PROMUS Eleme

3、nt Everolimus-Eluting Platinum Chromium Stent.14 Vernon is in control of his pain with the Precision Plus Spinal Cord Stimulator System(SCS).16 Danas treatment with the Genesys HTA System has given her new freedom and confidence.18 Pursuing Growth 22 Boston Scientific At-a-Glance24 Corporate Informa

4、tion WATCHMAN Left Atrial Appendage Closure Technology1 gives Boston Scientific an innovative product designed for atrial fibrillation patients with high stroke risk.1 In the U.S.,the WATCHMAN Device is an investigational device and is limited by applicable law to investigational use only and is not

5、 available for sale.Pursuing Growth through Innovation and Market ExpansionAs we pursue our mission of improving patients lives,innovation and market expansion are fundamental to our growth strategy.The Boston Scientific development pipeline is filled with innovative products and we expect that thes

6、e products and our expansion in emerging markets will fuel our growth for years to come.Icon denotes additional information online at on or connected to our website(or the website of any third-party)referenced in this Annual Report is in addition to and not a part of or incorporated by reference int